About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 639391, 5 pages
http://dx.doi.org/10.1155/2013/639391
Clinical Study

The Effect of Ranitidine on Olanzapine-Induced Weight Gain

1Clinical Psychiatry Research Center, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran
2Neuroscience Research Center, Department of Statistics & Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran
3Department of Public Health Sciences, WHO Collaborating Center for Safe Communities, Karolinska Institute, 171 76 Stockholm, Sweden

Received 6 April 2013; Revised 24 May 2013; Accepted 27 May 2013

Academic Editor: Akito Tanoue

Copyright © 2013 Fatemeh Ranjbar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Induced weight gain is a disturbing side effect of Olanzapine that affects the quality of life in psychotic patients. The aim of this study was to assess the efficacy of Ranitidine in attenuating or preventing Olanzapine-induced weight gain. A parallel 2-arm clinical trial was done on 52 patients with schizophrenia, schizoaffective and schizophreniform disorders who received Olanzapine for the first time. All these were first-episode admitted patients. They were randomly allocated to receive either Ranitidine or placebo. The trend of body mass index (BMI) was compared between groups over 16-week course of treatment. Mean weight was 62.3 (SD: 9.6) kg at baseline. Thirty-three subjects (63.5%) had positive family history of obesity. The average BMI increment was 1.1 for Ranitidine group and 2.4 for the placebo group. The multivariate analysis showed this effect to be independent of sex, family history of obesity, and baseline BMI value. The longitudinal modeling after controlling for baseline values failed to show the whole trend slope to be different. Although the slight change in trend’s slope puts forward a hypothesis that combined use of Ranitidine and Olanzapine may attenuate the weight gain long run, this needs to be retested in future larger scale long-term studies. This trial is registered with IRCT.ir 201009112181N5.